Recently, China’s National Medical Products Administration (NMPA) officially approved a novel domestically developed early lung cancer diagnostic test kit for market launch. Based on liquid biopsy technology, the kit detects specific methylation markers of circulating tumor DNA (ctDNA) in blood, enabling highly sensitive and specific screening at the earliest stages of lung cancer. Compared to conventional imaging methods, this approach is non-invasive, convenient, and highly repeatable—making it especially suitable for large-scale initial screening among high-risk populations.Clinical trial data show that the kit achieves a detection rate exceeding 85% for early-stage non-small cell lung cancer (NSCLC), with a false-positive rate below 5%, significantly outperforming existing alternatives. The developers state that this technology could shift the diagnostic window to Stage I or even earlier, substantially improving five-year survival rates. The kit is already being piloted in multiple top-tier hospitals across China and is expected to be integrated into the national cancer early-screening program.This breakthrough not only positions China among global leaders in cancer early detection but also provides strong support for achieving the ‘Healthy China 2030’ strategic goals. As costs decrease and accessibility expands, the test kit is poised to become a routine component of health check-ups, advancing the front line of lung cancer prevention and control.
近日，国家药品监督管理局正式批准了一款中国自主研发的新型肺癌早诊试剂盒上市。该试剂盒基于液体活检技术，通过检测血液中特定的循环肿瘤DNA（ctDNA）甲基化标志物，可在肺癌早期阶段实现高灵敏度和高特异性的筛查。与传统影像学检查相比，该方法具有无创、便捷、可重复性强等优势，特别适用于高危人群的大规模初筛。临床试验数据显示，该试剂盒对早期非小细胞肺癌（NSCLC）的检出率超过85%，假阳性率低于5%，显著优于现有同类产品。研发团队表示，该技术有望将肺癌诊断窗口提前至I期甚至更早，从而大幅提升患者五年生存率。目前，该试剂盒已在全国多家三甲医院开展试点应用，并计划纳入国家癌症早筛项目。这一突破不仅标志着我国在肿瘤早筛领域迈入国际先进行列，也为实现‘健康中国2030’战略目标提供了有力支撑。未来，随着成本进一步降低和普及推广，该试剂盒有望成为常规体检的重要组成部分，助力肺癌防控关口前移。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/22149.html